Agreement Termination Date

No definition available.

Name:	qlti_AgreementTerminationDate
Namespace Prefix:	qlti_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

The date that the Merger Agreement was signed with Auxilium Pharmaceuticals, Inc.

+ References

No definition available.

+ Details

Name:	qlti_DateMergerAgreementSigned
Namespace Prefix:	qlti_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Fee received by QLT from Auxilium Pharmaceuticals, Inc. in connection with the termination of the Merger Agreement.

+ References

No definition available.

+ Details

Name:	qlti_FeeReceivedInConnectionWithTerminationOfMergerAgreement
Namespace Prefix:	qlti_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Fee paid to the Company's financial advisor in connection with the termination of the Merger Agreement.

+ References

No definition available.

+ Details

Name:	qlti_FeesPaidInConnectionWithTerminationOfMergerAgreement
Namespace Prefix:	qlti_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Expected percentage of the Combined Company's common stock that would be owned by Auxilium Pharmaceuticals, Inc. under the terms of the contemplated Merger Agreement.

+ References

No definition available.

+ Details

Name:	qlti_PercentageOfCombinedCompanyStockOwned
Namespace Prefix:	qlti_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Terminated Merger Transaction with Auxilium - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended	0 Months Ended	3 Months Ended	9 Months Ended		0 Months Ended
	Sep. 30, 2014	Oct. 22, 2014 Subsequent Events [Member] Credit Suisse [Member]	Sep. 30, 2014 Selling, General and Administrative Expenses [Member]	Sep. 30, 2014 Selling, General and Administrative Expenses [Member]	Sep. 30, 2014 Auxilium [Member]	Oct. 09, 2014 Auxilium [Member] Subsequent Events [Member]
Business Acquisition [Line Items]
Merger Agreement date	Jun. 25, 2014
Percentage of Combined Company common shares expected to be owned by Auxilium Pharmaceuticals, Inc.					76.00%
Merger Agreement termination date	Oct. 08, 2014
Termination fee received						$ 28.4
Fees paid		5.7
Transaction fees			$ 1.2	$ 4.4